Coronavirus (COVID-19) News
Filter News
Found 2,554 articles
-
Biophytis Announces the Signature of a Master Service Agreement With Intsel Chimos, a Pharmaceutical Company That Will Operate Sarconeos (BIO101) in France for the Treatment of Severe Forms of COVID-19
3/2/2023
Biophytis SA announced that it has signed a master service agreement with the pharmaceutical company Intsel Chimos, which will become its Pharmaceutical Operator/Exploitant in France for Sarconeos in the context of the early access program application, requested for the treatment of severe forms of COVID-19, if approved.
-
Resverlogix Announces New Research Highlighting Apabetalone's Potential Benefits in Cardiovascular Disease, Heart Failure, and COVID-19
3/2/2023
Resverlogix Corp. (TSX: RVX) ("Resverlogix") today announced the publication of two articles in peer-reviewed scientific journals.
-
Biophytis Initiates the Regulatory Process for an Early Access Authorization in France from the French National Authority for Health (HAS) for the Treatment with Sarconeos (BIO101) of Severe Forms of COVID-19
2/27/2023
Biophytis SA, announced that it has begun the process of early access application in France from the French National Authority for Health for the treatment of severe COVID-19 with Sarconeos.
-
FDA Authorizes First Over-the-Counter At-Home Test to Detect Both Influenza and COVID-19 Viruses
2/24/2023
The U.S. Food and Drug Administration issued an emergency use authorization for the first over-the-counter at-home diagnostic test that can differentiate and detect influenza A and B, commonly known as the flu, and SARS-CoV-2, the virus that causes COVID-19.
-
Kinarus Therapeutics Phase 2 KINFAST Covid-19 Clinical Trial Progress Update
2/21/2023
Kinarus Therapeutics Holding AG, a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, provided an update on progress of its Phase 2 KINFAST trial of KIN001 in Covid-19.
-
Significant Progress Made on the Trivalent Recombinant Protein COVID-19 Vaccine against Subvariants including XBB.1.5 and BA.5 by WestVac Biopharma
2/20/2023
WestVac Biopharma Co., Ltd. has made significant progress on the development of the trivalent recombinant protein COVID-19 vaccine against the latest prevalent subvariants including XBB.1.5 and BA.5, which is one of the first trivalent recombinant protein vaccines targeting XBB.1.5 worldwide.
-
Can the Lingering Effects of a Mild Case of COVID-19 Change Your Brain
2/20/2023
People with long COVID who experience anxiety and depression months after a mild case of COVID-19 may have brain changes that affect the function and structure of the brain, according to a preliminary study released February 20, 2023, that will be presented at the American Academy of Neurology's 75th Annual Meeting being held in person in Boston and live online from April 22-27, 2023.
-
Health Canada Authorizes Moderna's Omicron-Targeting Bivalent COVID-19 Vaccine in Children & Adolescents (6-17 Years)
2/17/2023
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that Health Canada has authorized the use of its Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.214 in children and adolescents 6 to 17 years of age.
-
AIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, “Long Covid: What Will It Take To Accelerate Therapeutic Progress?”
2/17/2023
AIM ImmunoTech Inc., an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases — including COVID-19, the disease caused by the SARS-CoV-2 virus — announced it will participate in an event hosted by Solve M.E.
-
Tonix Pharmaceuticals to Participate in Event Titled, “Long COVID: What Will it Take to Accelerate Therapeutic Progress?”
2/16/2023
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present at a virtual event co-hosted by BIO and Solve M.E.
-
New Data Links Modulation of Key Immune-Related Proteins to Improvement of Specific Symptoms in Long COVID
2/16/2023
Data from a new clinical study show modulation of key immune regulating proteins with maraviroc and pravastatin correlates with symptom reduction in patients with post-acute sequelae of COVID, commonly known as long COVID.
-
Therma Bright Secures Exclusive License Agreement for AI4LYF's Patent-Pending Digital Cough Technology (DCT) to Detect Respiratory Diseases
2/16/2023
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma Bright" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies
-
Ginkgo Bioworks Announces Pathogen Monitoring Program at Kigali International Airport
2/15/2023
Ginkgo Bioworks and the Rwanda Biomedical Centre announced a one-year pathogen monitoring program at Rwanda's Kigali International Airport to identify new and emerging variants of SARS-CoV-2.
-
Shionogi Advances Ensitrelvir Fumaric Acid COVID-19 Antiviral Clinical Program
2/15/2023
Shionogi & Co., Ltd. announced progress on its comprehensive clinical development program for the novel COVID-19 oral antiviral ensitrelvir.
-
The COVID-19 research collaboration between Vir Biotechnology and GSK has largely come to an end, as Vir announced Monday it would be going it alone or with other partners. -
Clover Launches COVID-19 Booster Vaccine in the People’s Republic of China
2/14/2023
Clover Biopharmaceuticals, Ltd. announced that the launch of its COVID-19 vaccine, a recombinant SARS-CoV-2 subunit vaccine, in the People’s Republic of China has begun with the first doses delivered and administered in Changxing, Zhejiang as part of China’s national second booster dose campaign targeting older adults, immunocompromised individuals and individuals with comorbidities.
-
PDS Biotech Announces Publication of Preclinical Infectimune™ Based Vaccine Studies Demonstrating Effective Protection Against Viral Infection in Peer-Reviewed Journal, Viruses
2/8/2023
PDS Biotechnology Corporation announced that preclinical studies involving Infectimune™, PDS Biotech’s novel investigational immune activating platform, were published in the peer-reviewed journal, Viruses, demonstrating the technology’s ability to generate a broad immune response against viruses, including SARS-CoV-2 and multiple strains of influenza.
-
Biophytis Announces Positive Final Results of the Phase 2-3 COVA Study with Sarconeos (BIO101) in Severe COVID-19
2/2/2023
Biophytis SA, a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, released the final results from its phase 2-3 COVA clinical study evaluating Sarconeos in the treatment of COVID-19-related respiratory failure.
-
Axcella Therapeutics' Long COVID fatigue therapeutic is moving forward as the company received guidance from the MHRA and filed an IND with the FDA seeking a Phase IIb/III trial. -
Therma Bright Inc. Invests in Ischemic Stroke Blood Clot Retriever Technology Company Inretio Inc. based in Israel
1/19/2023
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma Bright" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it has signed a SPA (Share Purchase Agreement) with Inretio Ltd.